Kairos Pharma Ltd. (NYSE American: KAPA) has announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. This partnership aims to address a significant unmet medical need in advanced prostate cancer, where treatment resistance remains a major challenge.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. The company previously reported interim Phase 2 data showing a median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population.
The collaboration will explore whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer.
For business and technology leaders, this collaboration highlights the growing trend of combining targeted therapies with radiopharmaceuticals to overcome resistance mechanisms in oncology. The potential to extend progression-free survival and improve quality of life for patients could have significant implications for the prostate cancer treatment landscape, which is a multi-billion-dollar market. If successful, this combination could set a new standard of care and open avenues for similar approaches in other cancer types.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. It has not yet been approved by the FDA or any other regulator.
The full press release is available at https://ibn.fm/emSc4. For more information about Kairos Pharma, visit their newsroom at https://ibn.fm/KAPA.
